The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The move strengthens GBL’s clinical-stage presence in the United States
The companies aim to expand treatment options for millions living with metabolic disorders
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Subscribe To Our Newsletter & Stay Updated
